3-191375159-G-C
Variant summary
Our verdict is Likely benign. Variant got -6 ACMG points: 0P and 6B. BP4_ModerateBS2
The NM_178335.3(CCDC50):āc.546G>Cā(p.Glu182Asp) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000663 in 1,613,642 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 10/15 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (ā ā ).
Frequency
Consequence
NM_178335.3 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_benign. Variant got -6 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
CCDC50 | NM_178335.3 | c.546G>C | p.Glu182Asp | missense_variant | 6/12 | ENST00000392455.9 | |
CCDC50 | XM_011512460.2 | c.546G>C | p.Glu182Asp | missense_variant | 6/8 | ||
CCDC50 | NM_174908.4 | c.449-5000G>C | intron_variant |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
CCDC50 | ENST00000392455.9 | c.546G>C | p.Glu182Asp | missense_variant | 6/12 | 1 | NM_178335.3 | P3 | |
CCDC50 | ENST00000392456.4 | c.449-5000G>C | intron_variant | 1 | A1 |
Frequencies
GnomAD3 genomes AF: 0.0000592 AC: 9AN: 152140Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.0000360 AC: 9AN: 250332Hom.: 0 AF XY: 0.0000296 AC XY: 4AN XY: 135308
GnomAD4 exome AF: 0.0000671 AC: 98AN: 1461502Hom.: 0 Cov.: 31 AF XY: 0.0000536 AC XY: 39AN XY: 727046
GnomAD4 genome AF: 0.0000592 AC: 9AN: 152140Hom.: 0 Cov.: 32 AF XY: 0.0000269 AC XY: 2AN XY: 74318
ClinVar
Submissions by phenotype
not specified Uncertain:2
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Apr 07, 2023 | The c.546G>C (p.E182D) alteration is located in exon 6 (coding exon 6) of the CCDC50 gene. This alteration results from a G to C substitution at nucleotide position 546, causing the glutamic acid (E) at amino acid position 182 to be replaced by an aspartic acid (D). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. - |
Uncertain significance, criteria provided, single submitter | clinical testing | Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine | Jan 29, 2015 | The p.Glu182Asp variant in CCDC50 has not been previously reported in individual s with hearing loss, but has been identified in 3/67120 European chromosomes by the Exome Aggregation Consortium (ExAC, http://exac.broadinstitute.org; dbSNP rs 201472875). Although this variant has been seen in the general population, its f requency is not high enough to rule out a pathogenic role. Computational predict ion tools and conservation analyses suggest that the p.Glu182Asp variant may not impact the protein, though this information is not predictive enough to rule ou t pathogenicity. In summary, the clinical significance of the p.Glu182Asp varian t is uncertain. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at